ABT 2021 non-GAAP EPS=$5.21, above the prior guidance range of $5.00-5.10 due to a surge in COVID diagnostics sales in December related to Omicron.
ABT’s 2022 non-GAAP-EPS guidance is >=$4.70 (-10% YoY) due to lower expected sales of COVID diagnostics, which were $7.7B(!) in 2021 and $2.3B in 4Q21.